10-K: 22nd Century Group Reports FY2024 Results, Focuses on VLN and CMO Growth

22nd Century Group reports a decrease in net revenues for FY2024, but highlights strategic shifts towards VLN and contract manufacturing operations.

Summary

• 22nd Century Group's Form 10-K filing details the company's business, financial performance, and future strategies.
• The company focuses on reduced nicotine content (RNC) tobacco products, particularly VLN cigarettes, and contract manufacturing operations (CMO).
• Net revenues for FY2024 decreased by 24.3% to $24.38 million, primarily due to lower volumes of filtered cigars.
• The company is poised to benefit from the proposed FDA rule mandating reduced nicotine content in cigarettes.
• A new VLN product branding and marketing initiatives are planned to drive customer engagement.
• The company divested its GVB hemp/cannabis business in December 2023 to focus on tobacco operations.
• The company is restructuring contract manufacturing business operations to improve efficiency.
• The company signed a new license and manufacturing agreement with Smoker Friendly.
• The company is expanding the Pinnacle private label brand to add distribution of cigarillo products.
• The company executed two significant new export customer contracts to drive additional revenue.
• The company had a net loss of $15.49 million, or $105.85 per share, for FY2024, compared to a net loss of $54.69 million, or $5,776.63 per share, in FY2023.
• As of December 31, 2024, the company had $4.42 million in cash and cash equivalents.
• There is substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking strategic steps to improve its business and is poised to benefit from potential regulatory changes, it faces significant financial challenges and risks, including a history of losses and doubt about its ability to continue as a going concern.

Positives

• The company is poised to benefit from the proposed FDA rule mandating reduced nicotine content in cigarettes.
• The company divested its GVB hemp/cannabis business in December 2023 to focus on tobacco operations.
• The company signed a new license and manufacturing agreement with Smoker Friendly.
• The company is expanding the Pinnacle private label brand to add distribution of cigarillo products.
• The company executed two significant new export customer contracts to drive additional revenue.
• The company's net loss improved to $15.49 million in FY2024 from $54.69 million in FY2023.

Negatives

• The company's net revenues decreased by 24.3% to $24.38 million in FY2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of losses and expects to incur significant expenses and continuing losses for the foreseeable future.

Risks

• The company has a history of losses, and there is substantial doubt regarding its ability to continue as a going concern.
• The company may be unable to comply with the covenants in its convertible senior secured debentures.
• Competitors generally have greater financial resources and name recognition.
• The company may be unsuccessful in commercializing its RNC tobacco.
• The manufacturing and sale of tobacco products subjects the company to significant governmental regulation.
• The company may become subject to litigation related to cigarette smoking.
• The loss of a significant customer for whom the company manufactures tobacco products could have an adverse impact.
• The FDA could force the removal of the company's products from the U.S. market.
• The company may be unable to adequately protect its intellectual property.
• Nasdaq may delist the company's common stock.
• The company's stock price may be highly volatile.

Future Outlook

The company forecasts entering national distribution in 2025, with an eye eventually toward more than 270,000 domestic tobacco retail outlets and a substantial share of the estimated $12 billion non-Tier 1 US tobacco market.

Management Comments

• The company plans for new VLN product branding and marketing initiatives designed to drive greater customer engagement, as well as the development of partner VLN brands to be sold alongside proprietary VLN products.
• The company is restructuring contract manufacturing business operations to deliver improved efficiency and exited or renegotiated underpriced contracts in favor of improved customer agreements.

Industry Context

The announcement comes as the FDA is considering a proposed rule to mandate reduced nicotine content in all combustible cigarette products, which could significantly benefit 22nd Century Group due to its existing FDA-authorized low nicotine cigarettes.

Comparison to Industry Standards

• The company competes with major domestic and international tobacco companies such as Philip Morris USA Inc., Reynolds American Inc., and British American Tobacco.
• The company also competes with pharmaceutical companies in the market for FDA-approved smoking cessation aids, including Pfizer Inc. and GlaxoSmithKline plc.
• The company's VLN cigarettes compete with other reduced-risk tobacco products and alternative nicotine delivery systems.
• The company's contract manufacturing operations compete with other high-speed manufacturing facilities for tobacco products.

Legal Proceedings

• The company is involved in certain litigation matters, including shareholder derivative cases, a class action, an insurance litigation, a KeyGene dispute, a Cookies Retail Products dispute, and an employee dispute.
• The company has recorded an accrual for litigation settlement and corresponding indemnification receivable on the Consolidated Balance Sheets as of December 31, 2024 and 2023.

Related Party Transactions

• Beginning in the fourth quarter of 2024, the company recorded $154 of revenue , net and corresponding contract asset with a related party contract manufacturing customer for the sale of private label cigarettes.

Stakeholder Impact

• Shareholders face the risk of dilution from future sales of common stock and the exercise of outstanding warrants and notes.
• Employees may be affected by restructuring activities and cost-cutting initiatives.
• Customers may benefit from new VLN product branding and marketing initiatives.
• Suppliers may be affected by changes in the company's contract manufacturing operations.

Next Steps

• The company intends to submit comments and to be prominent and active in support of the proposed FDA rule to limit nicotine content in cigarettes.
• The company plans to employ consistent marketing collateral combined with a comprehensive digital market campaign, targeting adult smokers to drive point purchase direction with connectivity through age-gated social media platforms and an interactive website for adult smokers.
• The company will build its singular House of Brands by strategic increments, with time-to-market and profitability as its measures of success.

Key Dates

Keywords

VLN, tobacco, cigarettes, RNC, contract manufacturing, FDA, nicotine, MRTP, CMO, 22nd Century Group